INIT: First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market

About this update from Initiator Pharma A/s

A novel drug targeting monoamines is advancing through clinical trials for vulvodynia, a large unmet need in women's health, with a first-in-class approach and strong safety profile. The program is well-financed, with a pivotal trial underway and significant market potential projected.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Initiator Pharma A/s